Daniel Lenihan, MD, FACC, FESC, FIC-OS, a cardio-oncologist and founder of the International Cardio-Oncology Society, discusses cardiovascular risks associated with Bruton's tyrosine kinase inhibitors in...
Daniel Lenihan, MD, FACC, FESC, FIC-OS, a cardio-oncologist and founder of the International Cardio-Oncology Society, discusses cardiovascular risks associated with Bruton's tyrosine kinase inhibitors in...
Daniel Lenihan, MD, FACC, FESC, FIC-OS, a cardio-oncologist and founder of the International Cardio-Oncology Society, discusses cardiovascular risks associated with Bruton's tyrosine kinase inhibitors in...
Junaid Anwar, MD, discusses a meta-analysis of five landmark trials evaluating Janus kinase inhibitors for myelofibrosis, highlighting first-line efficacy and tolerability with ruxolitinib, second-line...
Junaid Anwar, MD, discusses a meta-analysis of five landmark trials evaluating Janus kinase inhibitors for myelofibrosis, highlighting first-line efficacy and tolerability with ruxolitinib, second-line...
Junaid Anwar, MD, discusses a meta-analysis of five landmark trials evaluating Janus kinase inhibitors for myelofibrosis, highlighting first-line efficacy and tolerability with ruxolitinib, second-line...
Junaid Anwar, MD, discusses a meta-analysis of five landmark trials evaluating Janus kinase inhibitors for myelofibrosis, highlighting first-line efficacy and tolerability with ruxolitinib, second-line...
Junaid Anwar, MD, discusses a meta-analysis of five landmark trials evaluating Janus kinase inhibitors for myelofibrosis, highlighting first-line efficacy and tolerability with ruxolitinib, second-line...
Junaid Anwar, MD, discusses a meta-analysis of five landmark trials evaluating Janus kinase inhibitors for myelofibrosis, highlighting first-line efficacy and tolerability with ruxolitinib, second-line...
Shanti Eswaran, MD, and Joel Heidelbaugh, MD, share evidence-based strategies to help primary care clinicians diagnose and manage IBS and chronic constipation with confidence.
